{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:28:26Z","timestamp":1788449306523,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Placenta"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.placenta.2024.12.010","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:29:10Z","timestamp":1734766150000},"page":"146-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-1813","authenticated-orcid":false,"given":"Jennifer H.","family":"Yo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten R.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nikolic-Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.placenta.2024.12.010_bib1","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.placenta.2024.12.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.placenta.2024.12.010_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.placenta.2024.12.010_bib4","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/HYPERTENSIONAHA.116.06421","article-title":"Angiogenic factors in preeclampsia: from diagnosis to therapy","volume":"67","author":"Karumanchi","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib5","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.placenta.2024.12.010_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.placenta.2024.12.010_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2014.11.009","article-title":"Molecular mechanisms of maternal vascular dysfunction in preeclampsia","volume":"21","author":"Goulopoulou","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.placenta.2024.12.010_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Special Issue: KDIGO clinical Practice guideline for the care of kidney transplant recipients","volume":"9","author":"Eckardt","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.placenta.2024.12.010_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.placenta.2024.12.010_bib10","series-title":"The Mechanism of Action of Cyclosporin A and FK506","author":"Lin","year":"1991"},{"key":"10.1016\/j.placenta.2024.12.010_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK\u2010506 and Cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.placenta.2024.12.010_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.placenta.2024.12.010_bib13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.placenta.2024.12.010_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/ki.2008.697","article-title":"Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect","volume":"75","author":"Cook","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.placenta.2024.12.010_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000257914.80918.72","article-title":"FK506 binding protein 12\/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure","volume":"49","author":"Long","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000339494","article-title":"Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change","volume":"35","author":"Kidokoro","year":"2013","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.placenta.2024.12.010_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20040474","article-title":"Nuclear factor of activated T cells balances angiogenesis activation and inhibition","volume":"199","author":"Zaichuk","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.placenta.2024.12.010_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020412","article-title":"The Role of calcineurin\/NFAT in SFRP2 induced angiogenesis-A rationale for breast cancer treatment with the calcineurin inhibitor Tacrolimus","volume":"6","author":"Siamakpour-Reihani","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.placenta.2024.12.010_bib19","doi-asserted-by":"crossref","first-page":"50537","DOI":"10.1074\/jbc.M406454200","article-title":"Vascular endothelial growth factor- and thrombin-induced termination factor, down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis","volume":"279","author":"Minami","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.placenta.2024.12.010_bib20","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/ajt.13773","article-title":"Timing of pregnancy after kidney transplantation and risk of Allograft Failure","volume":"16","author":"Rose","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.placenta.2024.12.010_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30913","article-title":"Adverse pregnancy Outcomes in solid organ transplant recipients","volume":"7","author":"Yo","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.placenta.2024.12.010_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0b013e3182708edf","article-title":"Pharmacokinetics of tacrolimus during pregnancy","volume":"34","author":"Zheng","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.placenta.2024.12.010_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nprot.2007.54","article-title":"A protocol for isolation and culture of human umbilical vein endothelial cells","volume":"2","author":"Baudin","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.placenta.2024.12.010_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/357695a0","article-title":"Identification of calcineurin as a key signalling enzyme in T","author":"Clipstone","year":"1992","journal-title":"Iymphocyte activation LETTERS TO NATURE"},{"key":"10.1016\/j.placenta.2024.12.010_bib25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/HYPERTENSIONAHA.110.162917","article-title":"Fk506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension","volume":"57","author":"Chiasson","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib26","author":"Takeda"},{"key":"10.1016\/j.placenta.2024.12.010_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/HYPERTENSIONAHA.110.162917","article-title":"Fk506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension","volume":"57","author":"Chiasson","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000257914.80918.72","article-title":"FK506 binding protein 12\/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure","volume":"49","author":"Long","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib29","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/ATVBAHA.107.144808","article-title":"Removal of Fkbp12\/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction","volume":"27","author":"Long","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.placenta.2024.12.010_bib30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/jhh.2017.61","article-title":"Placental growth factor and pre-eclampsia","volume":"31","author":"Chau","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.placenta.2024.12.010_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.placenta.2024.12.010_bib32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/HYPERTENSIONAHA.107.097790","article-title":"Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin\/nuclear factor of activated T-cells signaling","volume":"51","author":"Zhou","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.placenta.2024.12.010_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.placenta.2016.10.013","article-title":"Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta","volume":"48","author":"Ye","year":"2016","journal-title":"Placenta"},{"key":"10.1016\/j.placenta.2024.12.010_bib34","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm.1877","article-title":"Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma","volume":"14","author":"Jinnin","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.placenta.2024.12.010_bib35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/TP.0000000000002931","article-title":"Recipient Comorbidity and survival Outcomes after kidney transplantation: a UK-wide Prospective Cohort study","volume":"104","author":"Wu","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.placenta.2024.12.010_bib36","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1681\/ASN.2005040439","article-title":"Comorbid conditions in kidney transplantation: Association with graft and patient survival","volume":"16","author":"Wu","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.placenta.2024.12.010_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tiv.2018.07.017","article-title":"Tacrolimus inhibits angiogenesis and induces disaggregation of endothelial cells in spheroids \u2013 toxicity testing in a 3D cell culture approach","volume":"53","author":"Thoms","year":"2018","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.placenta.2024.12.010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2022.104446","article-title":"Angiogenesis modulation-mediated inhibitory effects of tacrolimus on hypertrophic scar formation","volume":"145","author":"Shen","year":"2023","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.placenta.2024.12.010_bib39","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1007\/s00204-017-2045-3","article-title":"Adverse outcome pathways: opportunities, limitations and open questions","volume":"91","author":"Leist","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.placenta.2024.12.010_bib40","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00204-019-02492-9","article-title":"Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations","volume":"93","author":"Albrecht","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.placenta.2024.12.010_bib41","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1007\/s00204-018-2302-0","article-title":"Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes","volume":"92","author":"Gu","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.placenta.2024.12.010_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00204-020-02669-7","article-title":"In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity","volume":"94","author":"Hengstler","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.placenta.2024.12.010_bib43","series-title":"Pharmacology in Drug Discovery","first-page":"125","article-title":"Pharmacokinetics I","author":"Kenakin","year":"2012"}],"container-title":["Placenta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400424008014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400424008014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T17:18:06Z","timestamp":1736615886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143400424008014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"alternative-id":["S0143400424008014"],"URL":"https:\/\/doi.org\/10.1016\/j.placenta.2024.12.010","relation":{},"ISSN":["0143-4004"],"issn-type":[{"value":"0143-4004","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor","name":"articletitle","label":"Article Title"},{"value":"Placenta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.placenta.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}